Information on Peptide “Medicines”
Contents
What peptides are and how they work
Peptides for diabetes and weight management
Peptides marketed for ageing and longevity
Semax and epitalon
Telomerase activation and cancer risk
Peptides marketed for male sexual health
Peptides marketed for female sexual health
Regulation, quality and patient safety
Practical safety advice
References
1. What peptides are and how they work
Peptides are short chains of amino acids (generally up to about 40–50 residues) that act as highly selective signaling molecules, and they have been mainstream drugs for a century: insulin, oxytocin, vasopressin, octreotide, leuprolide, and GLP-1 agonists are all peptides.[1][2]
Some peptides are established, highly effective medicines, such as insulin and GLP-1 medicines used for diabetes and obesity. Others are promoted online for healing, fat loss, muscle gain, ageing, sexual health or brain function, but have little or no reliable evidence in people.
This document explains the difference between regulated medicines and unapproved “research” or compounded products. It is general information, not personal medical advice. Do not start, stop or change a prescribed medicine without speaking to a clinician. People in the UK should follow UK product licences and NHS/NICE guidance; FDA information in this document applies to the United States.
More than 80 peptide drugs are FDA-approved, with over 170 in active development.[1] The premise that pharmaceutical companies are not producing them is therefore incorrect: industry makes peptides at enormous scale, with semaglutide and tirzepatide among the best-selling drugs in the world.[3] What industry is not developing are the wellness and "biohacking" peptides now in fashion (BPC-157, TB-500, CJC-1295, ipamorelin, and others). These have little or no controlled human evidence, are sold online as "research use only," and the FDA has restricted their compounding because of safety concerns.[2][4][5]
Peptides sit between small molecules and biologics in size. Most bind cell-surface receptors (often G protein–coupled receptors) and set off a signaling cascade inside the cell.[2][6] They fall into three groups:[1]
•Native peptides: identical to a natural hormone (e.g., insulin, oxytocin). They are well tolerated but usually have very short half-lives.
•Analogs: modified versions engineered to last longer, resist digestion, and bind their target more selectively (e.g., semaglutide, octreotide, desmopressin). These now dominate the clinical pipeline.
•Heterologous peptides: sequences found through screening or design, with no natural human counterpart. They can do new things but are more likely to cause unexpected side effects.
Main clinical uses
•Hormone replacement: for example, insulin in diabetes.[1]
•Receptor agonism or antagonism: in metabolic disease, oncology (GnRH analogs), endocrinology, bone disease, gastroenterology, and sexual dysfunction.[7]
•Diagnostics and theranostics: for example, radiolabeled somatostatin analogs used to image and treat neuroendocrine tumors.[8]
Why peptides have suddenly become so popular
There are two separate trends, and they are often confused.
1. Legitimate pharmaceutical success. GLP-1–based drugs changed the landscape. Semaglutide and tirzepatide now have approved indications in diabetes, obesity, cardiovascular risk reduction, CKD, obstructive sleep apnea, and MASH. Engineering advances such as fatty-acid conjugation, cyclization, and oral formulations solved the short half-life problem, and oral semaglutide shows that peptides can now be taken by mouth. The therapeutic peptide market was valued at $37.8 billion in 2022 and is projected to reach about $86 billion by 2031.[3][9][2]
2. The wellness and "biohacking" market. Social media influencers promote injectable peptides for tissue healing, muscle gain, fat loss, longevity, cognition, and sexual health. These products are sold online as "research chemicals" with scant evidence that any research is actually being done. The trend has been amplified by political signals. In February 2026 the HHS Secretary promised to loosen restrictions on up to 14 peptides. In July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed seven of them (BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, epitalon) for possible addition to the 503A compounding list.[2][5][4][10]
Why pharmaceutical companies are not developing the trendy peptides
•Weak evidence: most of these compounds have only animal data. Where human trials were done, they stalled or failed. BPC-157 never advanced beyond phase II. Ipamorelin showed no benefit over placebo for postoperative ileus. A phase II trial of CJC-1295 was stopped after a patient died of myocardial infarction.[2][5]
•Commercial barriers: many of these sequences are old, natural, or already public, so patent protection is weak. Without exclusivity, few companies will pay for phase III trials. Manufacturing complexity and regulatory requirements also hold back development of peptide drugs generally.[11][12]
•General peptide hurdles: these include poor oral bioavailability, susceptibility to protease breakdown, short half-life, immunogenicity, and high cost of production.[13][14]
Disadvantages of peptides as a drug class
•Instability: unmodified peptides are broken down by proteases (e.g., DPP-4, neprilysin) and often have plasma half-lives under 30 minutes.[15]
•Injection usually required: they are digested in the gut and cross membranes poorly. Achieving oral bioavailability often requires much higher doses.[13][15]
•Rapid clearance: the kidneys and liver remove them quickly.[15]
•Immunogenicity: this is a particular risk with non-human sequences (e.g., salmon calcitonin) and with synthesis impurities, which can create new T-cell epitopes.[15]
•Aggregation and storage problems: many need refrigeration.[16]
•Cost: synthesis and purification are expensive.[14]
Approved peptides: selected examples
1.Unapproved "wellness" peptides
Across this group, no long-term human safety data exist, gray-market products have documented problems with identity, purity, concentration, and sterility, and 503A compounders face no cGMP or adverse-event reporting requirements.[17][4][18] Most of these peptides are also prohibited by WADA.[18] In practice, clinicians should ask patients directly about peptide use. They should also separate biological plausibility from clinical proof, and offer approved alternatives where these exist, such as GLP-1 agonists for fat loss.[5]
2. Peptides for diabetes and weight management
The metabolic peptide market splits into three tiers. Tier 1 is FDA-approved incretin peptides (semaglutide, tirzepatide, liraglutide, dulaglutide), backed by robust RCT and outcome-trial evidence. Tier 2 is investigational incretins (retatrutide, cagrilintide/CagriSema, amylin agonists) that perform strongly in phase 3 trials but are being sold illegally before approval. Tier 3 is "wellness" peptides (AOD-9604, MOTS-c, BPC-157, thymosin β4, GH secretagogues, food-derived peptides) with little or no human efficacy data. Tirzepatide and semaglutide lower HbA1c by about 2%, produce roughly 15–21% weight loss, and reduce cardiovascular and kidney outcomes.[19][20][21] In contrast, AOD-9604 failed its obesity RCTs in more than 900 patients.[5] The ADA recommends against non-FDA-approved compounded GLP-1 products.[22] Compounded and black-market products carry higher reporting odds of contamination, hospitalization, and dosing errors.[23][22]
Tier 1: approved incretin peptides
The 2026 Annals meta-analysis (Moiz et al.) adds a caveat: weight regain after stopping is substantial. In STEP 1 extension data, about two-thirds of lost weight was regained within a year, so long-term therapy is required.[21]
The SURMOUNT-1 3-year figure shows tirzepatide's sustained weight loss and near-complete prevention of progression to T2D in prediabetes, followed by regain once treatment stopped.
Side effects of incretin peptides
•GI effects (most common): nausea 25–44%, diarrhea 19–30%, vomiting 8–24%, constipation 17–24%. These are concentrated in dose escalation, and fewer than 10% of patients discontinue for them.[24]
•Gallbladder/biliary disease: about 1.5-fold risk, higher with larger doses and longer use.[25]
•Pancreatitis: reported, but long-term RCTs show no clear excess over placebo.[25]
•Gastroparesis, bowel obstruction, and aspiration risk with retained gastric contents at anesthesia.[26][25]
•Diabetic retinopathy: worsening with rapid HbA1c reduction. NAION: rare signal.[26]
Peptide medicines
•Hypoglycemia only when combined with insulin or sulfonylureas, so those doses need reduction.[25]
•Boxed warning: thyroid C-cell tumors. Contraindicated with personal or family history of MTC or MEN2.
•Lean mass and bone loss with large weight loss, especially relevant in older adults. Protein intake and resistance training are recommended.[26][24]
•Pregnancy: not recommended. Stop before conception (semaglutide at least 2 months prior). Tirzepatide reduces oral contraceptive effectiveness during initiation and escalation.
Tier 2: investigational incretins sold illegally
•Retatrutide (GIP/GLP-1/glucagon triple agonist): phase 3 TRIUMPH-1 showed −25.0% weight loss at 12 mg vs −3.9% placebo at 80 weeks. In obesity plus T2D (TRIUMPH-2), weight loss was −18.8% vs −5.1%. In early T2D (TRANSCEND-T2D-1), HbA1c fell −1.94% vs −0.81%.[27][28][29]
•Retatrutide adverse effects: dose-related GI effects, heart rate increase, hypotension (6% at 12 mg), dysesthesia (7%), and discontinuation for adverse events up to 12%. Serious adverse events were more common than with placebo in the knee osteoarthritis trials.[28][30][31]
•Not FDA-approved. Black-market vials labeled "research use only" have uncertain potency and purity. At least 14 hospitalizations have been reported. Users online describe effects beyond those seen in trials (tachycardia, insomnia, muscle symptoms), possibly reflecting product quality or stacking.[32]
•Cagrilintide/CagriSema, eloralintide, zenagamtide (amylin-based): phase 3. Eloralintide is already sold online as a "research chemical".[32][33]
Tier 3: wellness peptides promoted for fat loss or glucose control
Compounded and gray-market risks across all tiers
•The ADA recommends against compounded GLP-1 and GIP/GLP-1 products and advises switching to another FDA-approved agent if there is a shortage. Compounded products may use salt forms such as semaglutide sodium or acetate, or include additives such as B12, without bioequivalence testing.[22]
•FAERS signals for compounded vs branded products: contamination ROR 19.0, preparation errors ROR 48.9, hospitalization ROR 2.35, and higher reporting of cholecystitis and suicidality.[23]
•Dosing errors of 5–20-fold from multidose vials and confusion over "units" have caused pancreatitis, gallstones, and hospitalization.[22]
Practical approach
•For T2D, obesity, or metabolic syndrome: prescribe FDA-approved semaglutide or tirzepatide. Choose based on ASCVD, CKD, MASH, or OSA, with tirzepatide giving greater HbA1c and weight reduction.[34][20]
•Screen for unapproved peptide use and ask about source, dose, and stacking. Report adverse events to MedWatch.[32][22]
•Steer patients away from AOD-9604, MOTS-c, and GH secretagogues for metabolic goals. GH-axis agents worsen glycemia in exactly the population being targeted.
3. Peptides marketed for ageing and longevity
The peptides most heavily promoted for "anti-aging" are epitalon, GHK-Cu, BPC-157, TB-500 and thymosin β4, Semax, the GH secretagogues (CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677), and the mitochondria-derived peptides (MOTS-c, humanin). Bremelanotide (PT-141) and GLP-1/GIP agonists such as tirzepatide are often bundled into longevity regimens as well. Only tirzepatide and bremelanotide have regulatory-grade human data, and neither is approved for aging.[35] For every other peptide, the evidence is preclinical or comes from small, uncontrolled, often developer-run studies, and there are no long-term safety data, validated dosing, or reliable product quality.[35] None has been shown to extend lifespan or healthspan in humans.
Summary by peptide
Main concerns that apply across these peptides
•Cancer risk from growth signaling: telomerase activators, GH/IGF-1 secretagogues, and angiogenic peptides (BPC-157, TB-500) all act on pathways that tumors exploit. GH promotes tumor invasion, resistance to therapy, and stemness in experimental models, and GH itself activates telomerase. Animal studies have not shown more cancer, but long-term human data do not exist.[36][37][38][35]
•Metabolic and cardiovascular effects of sustained GH elevation: these are a particular concern in older adults. Supporters argue that pulsatile secretagogues carry less risk than exogenous GH, but this is unproven.[39][35]
•Product quality: compounded and "research chemical" products have problems with identity, purity, concentration, sterility, and stacking of multiple agents. Use outside trials adds risks of infection, endotoxin exposure, and immunogenicity.[17][35][40]
•Weak evidence base: the Russian peptides (epitalon, thymalin, Semax) are backed by decades of use, but publication bias and weak pharmacovigilance mean the reported absence of adverse events does not establish safety.[35]
•Approved agents still carry their labeled risks: tirzepatide carries the boxed warning for thyroid C-cell tumors and is contraindicated with a personal or family history of MTC or MEN2. Pancreatitis, gallbladder disease, and loss of muscle and bone with weight loss are especially relevant in older adults.
4. Semax and epitalon
The evidence for both peptides is weak. Most of it is preclinical: rodent, cell-culture, and transcriptomic work. The human data come almost entirely from Russian studies by the developers' own groups, which are small, mostly unblinded or poorly reported, and have not been independently replicated. Both have been used in Russia for decades and appear well tolerated, but there is no systematic safety surveillance, and publication bias makes the reported absence of serious adverse events hard to interpret.[35][42] Neither is FDA-approved for any indication, and this underlies the FDA staff recommendation against listing them, which the PCAC overrode.[4][35]
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, given intranasally)
•What it is: a synthetic analog of the ACTH(4–10) fragment with a Pro-Gly-Pro tail added. It is reported to have no adrenal (corticotropic) activity. It is registered as a drug in Russia, where it is used for stroke and cognitive disorders.[35][43]
•Proposed mechanism (animal data): in rats, intranasal semax binds specific sites in the basal forebrain and raises BDNF protein there within 3 hours. Hippocampal BDNF protein rose about 1.4-fold and BDNF mRNA about 3-fold, with trkB activation.[35][44]
•Ischemia models: in rats with middle cerebral artery occlusion, semax reduced inflammatory gene expression, increased expression of neurotransmission genes, and altered genes involved in VEGF signaling and vascular function. These are transcriptomic changes, not functional outcomes.[45][46][43][47]
•Human data: Russian trials in elderly stroke patients reported better neurological recovery, rehabilitation, and cognition when semax was added to standard care. The regimen cited was two 10-day courses of 6,000 mcg/day, separated by 20 days. Randomized, blinded, Western-standard trials with hard endpoints such as mRS or mortality are lacking.[35]
•Proposed PCAC indications were cerebral ischemia, migraine, and trigeminal neuralgia. Rigorous human data are essentially absent for migraine and trigeminal neuralgia.[48]
Epitalon (Ala-Glu-Asp-Gly)
•What it is: a synthetic tetrapeptide designed to mimic Epithalamin, a crude extract of bovine pineal gland, developed by Khavinson's group in St. Petersburg.[42]
•Proposed mechanism (cell data): in human cell lines, epitalon induced hTERT and telomerase activity and lengthened telomeres. In breast cancer lines (21NT, BT474), it lengthened telomeres through ALT activation. The finding in cancer cells is a theoretical oncologic concern for a drug promoted for anti-aging.[35][49]
•Animal data: rodent studies reported 12–24% extension of median and maximum lifespan, and higher antioxidant enzyme activity. In old rhesus monkeys, melatonin and cortisol rhythms were restored. These come largely from the developer's laboratory.[35][42]
•Human data:
•Retinitis pigmentosa: parabulbar injection of 5 µg per eye for 10 days was reported to improve visual acuity and visual fields, with no adverse effects reported.[35]
•Melatonin and circadian rhythm: sublingual dosing of 0.5 mg/day for 20 days raised melatonin and changed circadian gene expression (Clock, Cry2, Csnk1e). These are surrogate markers, not sleep outcomes.[35]
•"Geroprotection": claims of reduced mortality in older adults rest mostly on Epithalamin, the extract, rather than epitalon, and on non-randomized cohorts from the same group.[42]
•Proposed PCAC indication was insomnia. No controlled trials with validated sleep outcomes (PSG or ISI) support it.[48]
Shared limitations
•Single source: almost all of the data come from the groups that developed each peptide.[35]
•No long-term safety data, and no defined dosing or pharmacokinetics in Western populations.[35]
•Unreliable products: compounded and gray-market supplies carry risks of impurity, poor sterility, and inconsistent dosing.[35]
•Theoretical risks: for epitalon, oncogenic risk from telomerase and ALT activation. For semax, long-term effects of neurotrophic and immune modulation are unknown.[49][43]
For patient counseling, both peptides are biologically plausible, but neither has robust clinical evidence. Patients with stroke, migraine, or insomnia should be steered to guideline-based therapies with proven benefit.
5. Telomerase activation and cancer risk
Telomerase activation is a theoretical but biologically credible cancer risk. It has not been shown to cause cancer in humans, and it has not been shown to be safe either. Three lines of evidence make the concern real. About 85–90% of human cancers depend on reactivating TERT.[38][50] Mendelian randomization (MR) studies consistently find that genetically longer telomeres raise the risk of several cancers.[51][52] And epitalon specifically lengthened telomeres in breast cancer cell lines through ALT activation.[49] Against that, the human interventional data are only short-term safety data. The largest dataset, TA-65 trials lasting up to 12 months, found no cancer signal, but these trials were not designed or powered to detect one.[53] No long-term human data exist for epitalon or any other telomerase activator.
Why telomerase is oncologically relevant
•Short telomeres act as a brake on cancer. Most somatic cells keep TERT switched off. As telomeres shorten, cells enter replicative senescence, which blocks the unlimited division a tumor needs.[54][55]
•How cancers escape: most reactivate telomerase through TERT promoter mutations (C228T, C250T), amplification, or epigenetic derepression. The other 10–15% mostly use ALT instead.[50][56][57]
•Effects beyond telomere length: TERT also affects mitochondrial function, DNA repair, gene transcription, and resistance to apoptosis. Each of these could favor a tumor regardless of telomere length.[54][58]
•Timing in carcinogenesis: in many cancers, telomerase reactivation is a late, enabling step. It lets cells that have already passed through telomere crisis and genomic instability keep dividing. The theoretical worry is that an activator could rescue rare premalignant clones that would otherwise die once their telomeres became critically short.[38][59]
Human genetic evidence: longer telomeres and cancer
•Large MR meta-analysis (62 studies, 396 associations): robust evidence linked longer genetically determined telomere length to higher risk of 24 neoplasms. The strongest associations were for osteosarcoma, glioblastoma, glioma, and thyroid cancer.[51]
•UK Biobank: longer genetically predicted telomere length was linked to melanoma, prostate, thyroid, and kidney cancers, sarcoma, and benign growths such as uterine fibroids. For lung cancer, the HR was 1.87 per SD, and 2.45 for adenocarcinoma, with the effect most prominent in never smokers.[52][60]
•Lung adenocarcinoma replicates across populations: OR 2.78 per 1,000 bp in one consortium, and ORs around 2 in East Asian cohorts. Other MR studies found associations with AML (OR roughly 2.6–4.0) and with Hodgkin lymphoma.[61][62][63][64][65]
•The trade-off: longer telomeres protect against coronary disease, CKD, pulmonary fibrosis, and other degenerative conditions. At the population level, the excess disease burden linked to long versus short telomeres is roughly equal.[51][52][66]
The 2017 JAMA Oncology Telomeres MR Collaboration figure shows this split. Genetically longer telomeres increase the odds of several cancers, most strongly glioma, low-malignancy-potential serous ovarian cancer, lung adenocarcinoma, and neuroblastoma, and decrease the odds of cardiovascular and other non-neoplastic diseases:
Key caveat in applying these data to drugs
These MR estimates reflect lifelong, inherited differences in telomere length. A short course of telomerase activation late in life is not the same exposure.[38] Some MR results are inconsistent across studies. One UK Biobank analysis, for example, found inverse associations for several cancers.[67] Long telomeres may also differ in how well they protect (cap) chromosome ends, which has not been measured.[38]
Preclinical and interventional data
•Transgenic mice: sustained TERT expression above physiologic levels expanded stem cell populations. After a long latency, it slightly increased the incidence of mammary tumors.[38]
•Mice given adult TERT restoration or long-term activators: cancer incidence did not rise over the study periods. These results do not establish safety across species, ages, or premalignant settings. TA-65 in older mice improved healthspan without a significant increase in overall cancer incidence.[38][68]
•TA-65 in humans: a meta-analysis of 8 RCTs (n = 750) found modest telomere lengthening (SMD 0.47). There was no improvement in frailty or inflammation. Only mild GI adverse effects were seen, with no cancer signal over 12 months, and long-term carcinogenic potential remains unaddressed. Effect sizes were inflated in industry-funded trials. Post-marketing reports of "no cancer" were not formally tracked.[53][59]
•Epitalon: it raised hTERT expression and telomerase activity in normal cells. In breast cancer cells (21NT, BT474), it induced ALT-mediated telomere lengthening, an effect specific to cancer cells. No human cancer-outcome data exist. The lifespan claims come almost entirely from the developer's laboratory.[49][35]
Clinical implications
•Highest theoretical risk: patients with active or previous cancer, known premalignant conditions such as clonal hematopoiesis, Barrett esophagus, or adenomas, a strong family cancer history, or germline cancer predisposition syndromes. Longer telomere length is itself causally linked to CHIP. Telomerase activators should be avoided in these patients.[51]
•Telomere length is not a validated treatment target. Lengthening telomeres with TA-65 did not translate into better function. Commercial telomere-length tests are not clinically actionable.[53]
•For counseling: describe the risk as uncertain, not as proven or absent. Telomere-targeted therapy will need carefully staged clinical studies with prospective biomarker and cancer surveillance before it can be considered safe.[38][69]
6. Peptides marketed for male sexual health
The peptides most often marketed to men for libido and erections are PT-141 (bremelanotide), Melanotan II, kisspeptin, and oxytocin. "Stacks" commonly add GH secretagogues (CJC-1295/ipamorelin), BPC-157, or gonadorelin as well. The melanocortin agonists (PT-141 and Melanotan II) have the most consistent human erectogenic data, including in sildenafil non-responders. Kisspeptin is an emerging option for low desire, and oxytocin results are mixed.[70] None of these is FDA-approved for any male indication. Bremelanotide (Vyleesi) is approved only for premenopausal women with HSDD, and its label states it is not indicated for men or to enhance sexual performance.[3] A 2026 systematic review found only 12 studies with 372 men in total, all small and short, with no head-to-head comparisons.[70] PDE5 inhibitors remain first-line.
Why melanocortins were never developed for men
Erections were first noticed as a side effect when melanotan was being studied for tanning. Development of melanocortins for ED stalled for two reasons: PDE5 inhibitors already worked, and the drugs caused nausea and raised blood pressure.[71] The intranasal formulation was abandoned because absorption varied and caused BP elevation.[72][73] The approved female dose is 1.75 mg s.c. 45 min before sex, no more than once per 24 h and 8 times per month. There is no validated male dose.[35] One theoretical advantage is that PT-141 does not cause the hypotension seen with PDE5 inhibitors.[74]
Safety points for counseling
•Blood pressure: bremelanotide raises BP transiently (mean peak about 3 mmHg systolic and diastolic, back to baseline by 12–24 h). It is contraindicated in uncontrolled hypertension or known cardiovascular disease, which describes much of the population with organic ED.[72]
•Pigmentation: MC1R activation darkens the skin, gums, and nevi. Melanotan II has been linked to atypical nevi and reports of melanoma, so a skin exam is reasonable in users.[72]
•Drug interactions: bremelanotide slows gastric emptying and lowers levels of oral naltrexone, so the combination should be avoided. Absorption of time-critical oral drugs may also be affected.
•Product quality: gray-market "research peptides" carry the same identity, contamination, and dosing risks discussed earlier.
•Missed diagnoses: new ED or low libido can be the first sign of cardiovascular disease, diabetes, hypogonadism, hyperprolactinemia, depression, or a medication effect. These need to be evaluated before treating the symptom.
Practical approach
Evaluate first (morning testosterone, glucose/HbA1c, lipids, CV risk), then use a PDE5 inhibitor. If that fails, second-line options with real evidence are intracavernosal alprostadil or trimix, a vacuum device, or a penile prosthesis. Off-label PT-141 is at most a carefully discussed option for PDE5i failures with normal BP, and the evidence for that use comes from a single RCT of the intranasal form.[75]
7. Peptides marketed for female sexual health
The main peptides marketed to women for low libido are bremelanotide (PT-141/Vyleesi), Melanotan II, kisspeptin, and oxytocin (intranasal or vaginal). "Libido stacks" sold by wellness clinics may also add GH secretagogues or BPC-157. Bremelanotide is the only one that is FDA-approved, and its indication is narrow: acquired, generalized HSDD in premenopausal women. It is not indicated for postmenopausal women or to enhance sexual performance.[3] Even for the approved use, the benefit is modest. About 25% of women reported a meaningful increase in desire vs 17–18% on placebo.[76][71] Kisspeptin and oxytocin are still experimental, and Melanotan II has no female efficacy data and is sold only as an unregulated tanning product.
Summary by peptide
Bremelanotide in practice
•Dosing limits: no more than 1 dose per 24 h and 8 doses per month. Stop after 8 weeks if there is no improvement.[76][77]
•Contraindications: uncontrolled hypertension and known cardiovascular disease. Bremelanotide also reduces naltrexone exposure, so avoid it in women taking naltrexone-containing products.[76][78]
•Pigmentation: hyperpigmentation of the face, gums, and breasts may not resolve after stopping. Women with darker skin are at higher risk.[78]
•Other interactions: slowed gastric emptying can affect time-critical oral drugs. Alcohol did not add adverse effects or hypotension.[79]
•Comparison with flibanserin: flibanserin (Addyi) is the oral daily alternative for HSDD in women younger than 65, both pre- and postmenopausal. It is not a peptide.[3]
Practical approach
•Rule out other causes before diagnosing HSDD: depression, SSRIs, hormonal contraception, genitourinary syndrome of menopause or dyspareunia, hyperprolactinemia or thyroid disease, and relationship factors.
•First-line treatment: sex therapy or CBT, and local therapy for genitourinary syndrome of menopause.
•Postmenopausal HSDD: transdermal testosterone has the best evidence. Bremelanotide in this group is off-label.
•Pregnancy: avoid bremelanotide in pregnancy and stop it if pregnancy occurs. Use contraception during treatment.
•Gray-market products: discourage gray-market "PT-141," Melanotan II, and peptide stacks because of the risks discussed in previous answers (identity, purity, and dosing).
The RECONNECT integrated subgroup analysis shows a consistent bremelanotide effect across age, BMI, and testosterone strata:
8. Regulation, quality and patient safety
At its July 23–24, 2026 meeting, the FDA Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding 6 of the 7 peptides it reviewed to the 503A Bulks List: BPC-157, KPV, TB-500, MOTs-C, semax, and epitalon. Emideltide was rejected by a 7–6 vote. The FDA's own career scientists had recommended against listing all seven, because none of them could be adequately characterized, let alone shown to be safe or effective.[4] A committee vote is advisory only. A peptide is added to the Bulks List only after the FDA accepts the recommendation and completes rulemaking. Until then, the 2023 interim restriction on compounding these peptides, imposed over "significant safety risks," remains the baseline.[4] A further PCAC meeting was planned before February 2027 to consider more of the previously withdrawn peptides.[48]
What was reviewed, by proposed indication[48]
•Day 1: BPC-157 for ulcerative colitis; KPV for wound healing and inflammatory conditions; TB-500 for wound healing; MOTs-C for obesity and osteoporosis.
Peptide medicines
•Day 2: emideltide for opioid withdrawal, chronic insomnia, and narcolepsy; epitalon for insomnia; semax for cerebral ischemia, migraine, and trigeminal neuralgia.
FDA staff assessment
The FDA's briefing documents applied the four regulatory criteria for the Bulks List: physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding. The conclusion for each peptide was that it should "NOT be included" in the list.[4]
How the vote split
•New permanent members voted for listing in all six approved cases. All original members and all temporary members voted against, apart from one institutional representative who abstained on every vote as a matter of policy.[4]
•The emideltide vote failed only because one permanent member broke ranks, for reasons that are unclear.[4]
•Members who voted in favor cited the existing gray market, "medical freedom," and "the greater good." None of these is an accepted criterion for the Bulks List.[4]
Process concerns
•Committee composition: by March 2026 only 4 members remained. HHS then appointed 8 new members, over objections from FDA officials. At least 6 of the new members have ties to peptide businesses or clinics. One runs a clinic that had received an FDA warning letter.[4]
•Conflicts of interest: the FDA stated that it had issued no conflict-of-interest waivers for the meeting.[4]
•Public testimony was heavily weighted toward listing. On BPC-157, for example, 19 speakers were in favor and 3 against.[4]
•Political context: in February 2026 the HHS Secretary pledged to loosen restrictions on up to 14 peptides and described his own use of them. FDA Commissioner Makary resigned in May 2026.[4][48]
Implications if the FDA adopts the recommendations
•Patient safety: 503A pharmacies are not subject to cGMP, registration, adverse-event reporting, or labeling requirements. State oversight is limited.[4]
•Drug development: companies would have little reason to fund trials if compounders can sell the same peptides without generating evidence.[4]
•Precedent: large illegal sales could become grounds for legitimizing other substances, such as kratom or cannabidiol.[4]
•An inconsistency: at the same time, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list on the grounds that they are approved drugs.[48]
For clinical counseling, nothing in this outcome changes the evidence. These peptides still lack controlled human efficacy data and long-term safety data.[17][18] Gray-market products remain unregulated whatever happens to the Bulks List decision.[10]
9. Practical safety advice
What “research use only” really means
Products labelled “research use only”, “for laboratory use” or “not for human consumption” are not medicines approved for people. Buying them online does not make them safe, and it does not guarantee that the vial contains the stated substance, dose or purity.
Questions to ask before using a peptide
•Has it been approved for my condition, and in my country?
•Is there evidence from randomised trials in people—not only laboratory or animal studies?
•What are the known and unknown risks, including cancer, hormonal, cardiovascular, infection and allergic risks?
•Who is supplying it, is it licensed, and can I verify its identity, strength and sterility?
•Could it interact with my other medicines, including insulin, blood-pressure medicines or naltrexone?
•Is it prohibited in my sport, and could it affect my eligibility to compete?
•Am I pregnant, trying to become pregnant, breastfeeding, or planning surgery?
Injections and infection
Any injection carries a risk of infection, injury or contamination if it is not prepared and administered correctly. Use a new sterile needle and syringe for every injection, do not share equipment, and seek urgent medical advice for fever, spreading redness, severe pain, pus, or feeling very unwell after an injection.
Surgery and anaesthesia
GLP-1 medicines can delay stomach emptying. Even when someone has followed the usual fasting instructions, food may remain in the stomach and increase the risk of regurgitation or aspiration during anaesthesia or deep sedation. Tell your anaesthetist and surgical team about every GLP-1 or dual GIP/GLP-1 medicine, including semaglutide, tirzepatide and liraglutide, before an operation or procedure.
Do not stop a prescribed GLP-1 medicine without advice from the prescriber or surgical team. They will advise whether to pause it, for how long, and what replacement glucose treatment may be needed if you have diabetes.
If you are already using an unapproved peptide
Do not stop suddenly if it has been prescribed for a medical condition; contact the prescriber for advice. If you are using an online or “research” product, do not increase the dose or combine products without medical advice. Keep the packaging, note the product name, dose, injection site and dates, and tell your GP or specialist. Seek urgent care for chest pain, severe shortness of breath, fainting, severe allergic symptoms, confusion, severe abdominal pain, or a rapidly worsening illness.
A balanced view of weight and ageing
For most people, the interventions with the strongest evidence for healthy ageing are regular physical activity, resistance training, adequate protein and nutrition, sleep, not smoking, managing blood pressure and diabetes, and treating established disease with medicines proven in clinical trials. These measures have far stronger evidence for health and function than unapproved peptide products.
UK relevance
FDA compounding rules do not apply directly in the UK. UK readers should rely on MHRA-licensed products, NHS prescribing pathways and NICE guidance. The FDA material is included because much of the online peptide market and the source document are US-focused.
FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Available at: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Available at: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
FDA. Compounding and the FDA: Questions and Answers. Available at: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
FDA. FDA Requires Safety Labeling Changes for GLP-1 Receptor Agonists. Available at: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
NICE. Overweight and obesity management. Available at: https://www.nice.org.uk/guidance/ng246/resources/a-guide-for-prescribing-medicines-to-manage-overweight-and-obesity-15299628589/chapter/Medicine-options-for-weight-management-in-adults
NICE. Tirzepatide for treating type 2 diabetes. Available at: https://www.nice.org.uk/guidance/ta924/chapter/1-Recommendations
NICE. Type 2 diabetes in adults: management. Available at: https://www.nice.org.uk/guidance/ng28/chapter/Further-medication
NICE BNF. Tirzepatide. Available at: https://bnf.nice.org.uk/drugs/tirzepatide/
10. References
Numbered in order of first citation. Bibliographic details and URLs are taken from the supplied file; tracking parameters have been removed. They have not been independently authenticated.
1. Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. Shi M, McHugh KJ. Advanced Drug Delivery Reviews. 2023;199:114904. doi:10.1016/j.addr.2023.114904.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526705/
2. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Mayfield CK, Bolia IK, Feingold CL, et al. The American Journal of Sports Medicine. 2026;54(1):223-229. doi:10.1177/03635465251357593.
Source: https://doi.org/10.1177/03635465251357593
3. FDA Orange Book. FDA Orange Book.
Source: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. Peptides, FDA’s Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval. Samantaroy S, Xu I, Lurie P. JAMA. 2026;:2855793. doi:10.1001/jama.2026.19125.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.19125
5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Mendias CL, Awan TM. Sports Medicine (Auckland, N.Z.). 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0.
Source: https://doi.org/10.1007/s40279-026-02437-0
6. Peptide Therapeutics: Current Status and Future Opportunity With Focus on Nose-to-Brain Delivery☆. Jülke EM, Beck-Sickinger AG. Peptides. 2025;188:171404. doi:10.1016/j.peptides.2025.171404.
Source: https://pubmed.ncbi.nlm.nih.gov/40222598
7. Peptide‐based diagnostic and therapeutic agents: Where we are and where we are heading?. Khalily MP, Soydan M. Chemical Biology & Drug Design. 2023;101(3):772-793. doi:10.1111/cbdd.14180.
Source: https://doi.org/10.1111/cbdd.14180
8. Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges. Thakur R, Suri CR, Kaur IP, Rishi P. Critical Reviews in Therapeutic Drug Carrier Systems. 2022;40(1):49-100. doi:10.1615/CritRevTherDrugCarrierSyst.2022040322.
Source: https://pubmed.ncbi.nlm.nih.gov/36374841
9. In Vivo Degradation Forms, Anti-Degradation Strategies, and Clinical Applications of Therapeutic Peptides in Non-Infectious Chronic Diseases. Tasdemiroglu Y, Gourdie RG, He JQ. European Journal of Pharmacology. 2022;932:175192. doi:10.1016/j.ejphar.2022.175192.
Source: https://pubmed.ncbi.nlm.nih.gov/35981605
10. Illicit Injectable Peptides and Regulatory Gaps. Piatkowski T, Ganson KT, Nagata JM. JAMA. 2026;336(3):189-190. doi:10.1001/jama.2026.10690.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10690
11. Current Challenges in the Development of Therapeutic Peptides. Lee HT, Ho KL, Yong PVC, Lee SH. Current Protein & Peptide Science. 2026;:CPPS-EPUB-159762. doi:10.2174/0113892037539198261101194310.
Source: https://pubmed.ncbi.nlm.nih.gov/43023438
12. Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating From the Laboratory to Patients. Rafferty J, Nagaraj H, McCloskey AP, et al. Current Medicinal Chemistry. 2016;23(37):4231-4259. doi:10.2174/0929867323666160909155222.
Source: https://pubmed.ncbi.nlm.nih.gov/27633684
13. Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications. Lombardi L, Genio VD, Albericio F, Williams DR. Chemical Reviews. 2025;125(15):7099-7166. doi:10.1021/acs.chemrev.4c00989.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355721/
14. The Future of Peptide‐based Drugs. Craik DJ, Fairlie DP, Liras S, Price D. Chemical Biology & Drug Design. 2013;81(1):136-47. doi:10.1111/cbdd.12055.
Source: https://doi.org/10.1111/cbdd.12055
15. Peptide-based drugs in immunotherapy: current advances and future prospects. Karati D, Meur S, Das S, Adak A, Mukherjee S. Medical Oncology (Northwood, London, England). 2025;42(5):177. doi:10.1007/s12032-025-02739-9.
Source: https://doi.org/10.1007/s12032-025-02739-9
16. The evolution of commercial drug delivery technologies. Vargason AM, Anselmo AC, Mitragotri S. Nature Biomedical Engineering. 2021;5(9):951-967. doi:10.1038/s41551-021-00698-w.
Source: https://doi.org/10.1038/s41551-021-00698-w
17. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Tham A, Hodgkins CW, Kennedy JG. The Journal of the American Academy of Orthopaedic Surgeons. 2026;:00124635-990000000-01792. doi:10.5435/JAAOS-D-26-00049.
Source: https://pubmed.ncbi.nlm.nih.gov/42937313
18. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Tewari K, Liu TP, Im C, et al. The American Journal of Sports Medicine. 2026;:3635465261464420. doi:10.1177/03635465261464420.
Source: https://doi.org/10.1177/03635465261464420
19. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. De Block C, Bailey C, Wysham C, et al. Diabetes, Obesity & Metabolism. 2023;25(1):3-17. doi:10.1111/dom.14831.
Source: https://doi.org/10.1111/dom.14831
20. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Lancet (London, England). 2026;407(10531):892-908. doi:10.1016/S0140-6736(25)02105-1.
Source: https://pubmed.ncbi.nlm.nih.gov/41547366
21. Obesity Management in Adults: A Review. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.19897
22. Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Neumiller JJ, Bajaj M, Bannuru RR, et al. Diabetes Care. 2025;48(2):177-181. doi:10.2337/dci24-0091.
Source: https://doi.org/10.2337/dci24-0091
23. Safety Analysis of Compounded GLP-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. McCall KL, Mastro Dwyer KA, Casey RT, et al. Expert Opinion on Drug Safety. 2026;25(3):581-588. doi:10.1080/14740338.2025.2499670.
Source: https://pubmed.ncbi.nlm.nih.gov/40285721
Peptide medicines
24. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, et al. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.
Source: https://linkinghub.elsevier.com/retrieve/pii/S0002-9165(25)00240-0
25. GLP-1 Receptor Agonists. Rosen CJ, Ingelfinger JR. The New England Journal of Medicine. 2026;394(13):1313-1324. doi:10.1056/NEJMra2500106.
Source: https://doi.org/10.1056/nejmra2500106
26. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Kunutsor SK, Seidu S. Drugs. 2026;86(1):11-36. doi:10.1007/s40265-025-02263-0.
Source: https://doi.org/10.1007/s40265-025-02263-0
27. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Jastreboff AM, Kaplan LM, Davies MJ, et al. The New England Journal of Medicine. 2026;395(18):1781-1793. doi:10.1056/NEJMoa2604169.
Source: https://doi.org/10.1056/nejmoa2604169
28. Retatrutide in Adults With Obesity and Type 2 Diabetes (TRIUMPH-2): A Double-Blind, Parallel-Group, Randomised, Placebo-Controlled, Phase 3 Trial. Bellido V, le Roux CW, Ekinci EI, et al. Lancet (London, England). 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1.
Source: https://pubmed.ncbi.nlm.nih.gov/42810372
29. Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People With Type 2 Diabetes and Inadequate Glycaemic Control With Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial. Bajaj HS, Welch M, Shah P, et al. Lancet (London, England). 2026;407(10546):2402-2413. doi:10.1016/S0140-6736(26)00967-0.
Source: https://pubmed.ncbi.nlm.nih.gov/42250575
30. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. Jastreboff AM, Kaplan LM, Frías JP, et al. The New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
Source: https://doi.org/10.1056/nejmoa2301972
31. Retatrutide Once Weekly in Adults With Knee Osteoarthritis Pain and Obesity. Schnitzer TJ, Hunter DJ, Conaghan PG, et al. The New England Journal of Medicine. 2026;. doi:10.1056/NEJMoa2610676.
Source: https://pubmed.ncbi.nlm.nih.gov/43001755
32. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. Rubin R. JAMA. 2026;:2855339. doi:10.1001/jama.2026.20514.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.20514
33. Recent Advances in Peptide-Based Therapies for Obesity and Type 2 Diabetes. Bailey CJ, Flatt PR, Conlon JM. Peptides. 2024;173:171149. doi:10.1016/j.peptides.2024.171149.
Source: https://pubmed.ncbi.nlm.nih.gov/38184193
34. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes. Del Prato S, Heine RJ, Pérez Manghi FC, et al. Annals of Internal Medicine. 2026;179(7):917-928. doi:10.7326/ANNALS-25-05602.
Source: https://doi.org/10.7326/annals-25-05602
35. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Mavrych V, Shypilova I, Bolgova O. Frontiers in Aging. 2026;7:1790247. doi:10.3389/fragi.2026.1790247.
Peptide medicines
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095733/
36. Direct Activation of Telomerase by GH via Phosphatidylinositol 3'-Kinase. Gómez-García L, Sánchez FM, Vallejo-Cremades MT, de Segura IA, del Campo Ede M. The Journal of Endocrinology. 2005;185(3):421-8. doi:10.1677/joe.1.05766.
Source: https://pubmed.ncbi.nlm.nih.gov/15930168
37. Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Kopchick JJ, Basu R, Berryman DE, et al. Nature Reviews. Endocrinology. 2022;18(9):558-573. doi:10.1038/s41574-022-00702-6.
Source: https://doi.org/10.1038/s41574-022-00702-6
38. Positioning TERT at the apex of aging. DePinho RA. Nature Aging. 2026;6(8):1546-1553. doi:10.1038/s43587-026-01179-y.
Source: https://doi.org/10.1038/s43587-026-01179-y
39. The Role of Growth Hormone-Releasing Hormone and the Hypothalamic-Pituitary-Somatotropic Axis in Aging: Potential Therapeutic Applications and Risks. Oikonomakos I, Siow R, Bornstein SR, Steenblock C. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2025;. doi:10.1055/a-2641-1207.
Source: https://pubmed.ncbi.nlm.nih.gov/40645768
40. The Emerging Landscape of Performance-Enhancing Peptides Modulating GH-IGF1 Axis: Bridging the Gap Between Clinical Evidence and Patient Self-Administration. Dominikowski A, Rękoś Z, Olejarz M, et al. Frontiers in Endocrinology. 2026;17:1822475. doi:10.3389/fendo.2026.1822475.
Source: https://pubmed.ncbi.nlm.nih.gov/42395176
41. Biomarkers of aging: from molecules and surrogates to physiology and function. Furrer R, Handschin C. Physiological Reviews. 2025;105(3):1609-1694. doi:10.1152/physrev.00045.2024.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617729/
42. Peptides and Ageing. Khavinson VKh. Neuro Endocrinology Letters. 2002;23 Suppl 3:11-144.
Source: https://pubmed.ncbi.nlm.nih.gov/12374906
43. The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia: Genome-Wide Transcriptional Analysis. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228.
Source: https://pubmed.ncbi.nlm.nih.gov/24661604
44. Semax, an Analogue of Adrenocorticotropin (4-10), Binds Specifically and Increases Levels of Brain-Derived Neurotrophic Factor Protein in Rat Basal Forebrain. Dolotov OV, Karpenko EA, Seredenina TS, et al. Journal of Neurochemistry. 2006;97 Suppl 1:82-6. doi:10.1111/j.1471-4159.2006.03658.x.
Source: https://pubmed.ncbi.nlm.nih.gov/16635254
45. Novel Insights Into the Protective Properties of ACTHPGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Genes. 2020;11(6):E681. doi:10.3390/genes11060681.
Source: https://pubmed.ncbi.nlm.nih.gov/32580520
46. Semax, an Analog of ACTH, Regulates Expression of Immune Response Genes During Ischemic Brain Injury in Rats. Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV. Molecular Genetics and Genomics : MGG. 2017;292(3):635-653. doi:10.1007/s00438-017-1297-1.
Source: https://pubmed.ncbi.nlm.nih.gov/28255762
Peptide medicines
47. Effect of Semax and Its C-Terminal Fragment Pro-Gly-Pro on the Expression of VEGF Family Genes and Their Receptors in Experimental Focal Ischemia of the Rat Brain. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. Journal of Molecular Neuroscience : MN. 2013;49(2):328-33. doi:10.1007/s12031-012-9853-y.
Source: https://pubmed.ncbi.nlm.nih.gov/22772900
48. Under FDA, Unapproved Peptides Likely to Become More Widely Available. Rubin R. JAMA. 2026;335(22):1920-1921. doi:10.1001/jama.2026.6388.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6388
49. Epitalon Increases Telomere Length in Human Cell Lines Through Telomerase Upregulation or ALT Activity. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x.
Source: https://pubmed.ncbi.nlm.nih.gov/40908429
50. Telomere function and regulation from mouse models to human aging and disease. Jones-Weinert C, Mainz L, Karlseder J. Nature Reviews. Molecular Cell Biology. 2025;26(4):297-313. doi:10.1038/s41580-024-00800-5.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096892/
51. Association Between Genetically Determined Telomere Length and Health-Related Outcomes: A Systematic Review And meta-Analysis of Mendelian Randomization Studies. Chen B, Yan Y, Wang H, Xu J. Aging Cell. 2023;22(7):e13874. doi:10.1111/acel.13874.
Source: https://pubmed.ncbi.nlm.nih.gov/37232505
52. Polygenic basis and biomedical consequences of telomere length variation. Codd V, Wang Q, Allara E, et al. Nature Genetics. 2021;53(10):1425-1433. doi:10.1038/s41588-021-00944-6.
Source: https://doi.org/10.1038/s41588-021-00944-6
53. Effects of TA-65 on Telomere Length, Functional Outcomes, and Inflammation: A Systematic Review and Meta-Analysis. Su X, Wang C, Gou Z, Qu Y. Cell Biology and Toxicology. 2025;41(1):155. doi:10.1007/s10565-025-10115-6.
Source: https://pubmed.ncbi.nlm.nih.gov/41286474
54. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Yuan X, Larsson C, Xu D. Oncogene. 2019;38(34):6172-6183. doi:10.1038/s41388-019-0872-9.
Source: https://doi.org/10.1038/s41388-019-0872-9
55. Telomeres and Telomerase in Oncogenesis. Trybek T, Kowalik A, Góźdź S, Kowalska A. Oncology Letters. 2020;20(2):1015-1027. doi:10.3892/ol.2020.11659.
Source: https://pubmed.ncbi.nlm.nih.gov/32724340
56. TERT Amplification. Memorial Sloan Kettering. OncoKB. 2026.
Source: https://www.oncokb.org/gene/TERT/somatic/Amplification
57. TERT Promoter Mutation. Memorial Sloan Kettering. OncoKB. 2026.
Source: https://www.oncokb.org/gene/TERT/somatic/Promoter%20Mutation
58. Telomerase in Cancer- Ongoing Quest and Future Discoveries. Mishra A, Patel TN. Molecular Biology Reports. 2025;52(1):161. doi:10.1007/s11033-025-10251-6.
Source: https://pubmed.ncbi.nlm.nih.gov/39862360
59. A Natural Product Telomerase Activator as Part of a Health Maintenance Program: Metabolic and Cardiovascular Response. Harley CB, Liu W, Flom PL, Raffaele JM. Rejuvenation Research. 2013;16(5):386-95. doi:10.1089/rej.2013.1430.
Source: https://doi.org/10.1089/rej.2013.1430
60. Phenotypic and Genetically Predicted Leucocyte Telomere Length and Lung Cancer Risk in the Prospective UK Biobank. Wong JY, Blechter B, Hubbard AK, et al. Thorax. 2024;79(3):274-278. doi:10.1136/thorax-2023-220076.
Source: https://pubmed.ncbi.nlm.nih.gov/38238005
61. The Causal Relationship Between Telomere Length and Cancer Risk: A Two-Sample Mendelian Randomization. Lee SH, Song DS, Kim UC, Jee SH, Lee K. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2025;34(5):737-743. doi:10.1158/1055-9965.EPI-24-1168.
Source: https://pubmed.ncbi.nlm.nih.gov/40079752
62. Genetic Determinants of Telomere Length and Risk of Common Cancers: A Mendelian Randomization Study. Zhang C, Doherty JA, Burgess S, et al. Human Molecular Genetics. 2015;24(18):5356-66. doi:10.1093/hmg/ddv252.
Source: https://pubmed.ncbi.nlm.nih.gov/26138067
63. Mendelian Randomization and Mediation Analysis of Leukocyte Telomere Length and Risk of Lung and Head and Neck Cancers. Kachuri L, Saarela O, Bojesen SE, et al. International Journal of Epidemiology. 2019;48(3):751-766. doi:10.1093/ije/dyy140.
Source: https://pubmed.ncbi.nlm.nih.gov/30059977
64. The Causal Effect of Telomere Length on the Risk of Malignant Lymphoma: A Mendelian Randomization Study. Song T, Liu J, Zhao K, et al. Medicine. 2024;103(38):e39584. doi:10.1097/MD.0000000000039584.
Source: https://pubmed.ncbi.nlm.nih.gov/39312382
65. Predicted Leukocyte Telomere Length and Risk of Myeloid Neoplasms. Sullivan SM, Cole B, Lane J, et al. Human Molecular Genetics. 2023;32(20):2996-3005. doi:10.1093/hmg/ddad126.
Source: https://pubmed.ncbi.nlm.nih.gov/37531260
66. Are Long Telomeres Better Than Short? Relative Contributions of Genetically Predicted Telomere Length to Neoplastic and Non-Neoplastic Disease Risk and Population Health Burden. Protsenko E, Rehkopf D, Prather AA, Epel E, Lin J. PloS One. 2020;15(10):e0240185. doi:10.1371/journal.pone.0240185.
Source: https://pubmed.ncbi.nlm.nih.gov/33031470
67. Assessing the Relationship Between Leukocyte Telomere Length and Cancer Risk/Mortality in UK Biobank and TCGA Datasets With the Genetic Risk Score and Mendelian Randomization Approaches. Gao Y, Wei Y, Zhou X, et al. Frontiers in Genetics. 2020;11:583106. doi:10.3389/fgene.2020.583106.
Source: https://pubmed.ncbi.nlm.nih.gov/33193711
68. The Telomerase Activator TA-65 Elongates Short Telomeres and Increases Health Span of Adult/Old Mice Without Increasing Cancer Incidence. Bernardes de Jesus B, Schneeberger K, Vera E, et al. Aging Cell. 2011;10(4):604-21. doi:10.1111/j.1474-9726.2011.00700.x.
Source: https://pubmed.ncbi.nlm.nih.gov/21426483
69. Telomerase activation and human health-span: an open issue. Boccardi V, Mecocci P. Aging Clinical and Experimental Research. 2018;30(2):221-223. doi:10.1007/s40520-017-0766-z.
Source: https://doi.org/10.1007/s40520-017-0766-z
Peptide medicines
70. Peptides for Male Sexual Dysfunction: A Systematic Review of Emerging Evidence. Ramez M, Mostafa MM, Mohamed H, et al. The Journal of Sexual Medicine. 2026;23(12):qdag338. doi:10.1093/jsxmed/qdag338.
Source: https://pubmed.ncbi.nlm.nih.gov/43002584
71. Targeting the central melanocortin system for the treatment of metabolic disorders. Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Nature Reviews. Endocrinology. 2023;19(9):507-519. doi:10.1038/s41574-023-00855-y.
Source: https://doi.org/10.1038/s41574-023-00855-y
72. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Mayer D, Lynch SE. The Annals of Pharmacotherapy. 2020;54(7):684-690. doi:10.1177/1060028019899152.
Source: https://doi.org/10.1177/1060028019899152
73. Bremelanotide: First Approval. Dhillon S, Keam SJ. Drugs. 2019;79(14):1599-1606. doi:10.1007/s40265-019-01187-w.
Source: https://doi.org/10.1007/s40265-019-01187-w
74. Melanocortins in the Treatment of Male and Female Sexual Dysfunction. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Current Topics in Medicinal Chemistry. 2007;7(11):1137-44. doi:10.2174/156802607780906681.
Source: https://pubmed.ncbi.nlm.nih.gov/17584134
75. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. Safarinejad MR, Hosseini SY. The Journal of Urology. 2008;179(3):1066-71. doi:10.1016/j.juro.2007.10.063.
Source: https://pubmed.ncbi.nlm.nih.gov/18206919
76. Another Option for Hypoactive Sexual Desire. Sancar F. JAMA. 2019;322(7):604. doi:10.1001/jama.2019.11515.
Source: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.11515
77. Vyleesi. Food and Drug Administration. Updated date: 2026-11-05.
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
78. Current and future pharmacotherapy for female sexual dysfunction. Reisman Y, Dubinskaya A, Padoa A. Nature Reviews. Urology. 2026;23(2):133-147. doi:10.1038/s41585-025-01076-w.
Source: https://doi.org/10.1038/s41585-025-01076-w
79. Pharmacotherapy for Sexual Dysfunction in Women. Lee JH, Lee JE, Harsh V, Clayton AH. Current Psychiatry Reports. 2022;24(2):99-109. doi:10.1007/s11920-022-01322-7.
Source: https://doi.org/10.1007/s11920-022-01322-7